726206-53-7

Basic information

• Product Name: 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde
• Synonyms: 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde;1,2-dihydro-4-iodo-2-oxopyridine-3-carbaldehyde;2-HYDROXY-4-IODONICOTINALDEHYDE
• CAS NO: 726206-53-7
• Molecular Formula: C₆H₄INO₂
• Molecular Weight: 249.00593
• Mol File: 726206-53-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 345.7±42.0 °C(Predicted)
• Appearance: /
• Density: 2.11±0.1 g/cm3(Predicted)
• PKA: 8.92±0.10(Predicted)
• CAS DataBase Reference: 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde(726206-53-7)
• EPA Substance Registry System: 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde(726206-53-7)

Safety Data

• Hazardous Substances Data: 726206-53-7(Hazardous Substances Data)

Usage

General Description

4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde is a chemical compound with the molecular formula C6H5IN2O2. It is a yellow powdery substance that is commonly used in organic synthesis and pharmaceutical research. 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde is a versatile building block in the production of various pharmaceuticals, agrochemicals, and other fine chemicals. Its unique structure and reactivity make it a valuable tool for chemists and researchers looking to develop new compounds and drugs. It is also used as a precursor in the synthesis of pyridine derivatives and other heterocyclic compounds. Due to its potential as a key intermediate in organic chemistry, 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde is of significant interest in the scientific community.

Upstream product

• 1628-89-3 2-methoxypyridine 
• 158669-26-2 4-iodo-2-methoxynicotinaldehyde 

Downstream Products

• 1025721-07-6 1-(4-fluorophenyl)-4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde 
• 1025720-94-8 BMS-777607 
• 1439877-05-0 N-(4-((2-acetamidopyridin-4-yl)oxy)-2,5-difluorophenyl)-1-(4-fluorophenyl)-4-(methylamino)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1439878-82-6 1-(4-fluorophenyl)-4-iodo-2-oxo-1,2-dihydropyridine-3-carboxylic acid [4-(2-acetylaminopyridin-4-yloxy)-2,5-difluorophenyl]amide 
• 1439878-75-7 N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-1-(4-fluorophenyl)-4-iodo-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1439876-98-8 N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-4-(ethylamino)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1025721-21-4 1-(4-fluoro-phenyl)-4-iodo-2-oxo-1,2-dihydro-pyridine-3-carbonyl chloride 
• 1025721-10-1 1-(4-fluoro-phenyl)-4-iodo-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid 

Relevant articles and documents

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Formula (I). Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4- ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the met kinase superfamily

Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)- 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors. Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aqueous solubility and kinase selectivity. Analogue 10 demonstrated complete tumor stasis in a Met- dependent GTL-16 human gastric carcinoma xenograft model following oral administration. Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclinical safety profiles, 10 has been advanced into phase I clinical trials.